Despite a challenging fundraising environment, Hatteras Venture Partners successfully closed two new funds totaling $200 million targeting seed and early-stage biotech companies. This injection of capital is poised to fuel innovation and early development in the life sciences sector. The funds complement a broader trend of cautious but continued investment activity amid uncertainties in public markets and biopharma financing.